Cipla on Monday, January 22, posted quarterly revenue of ₹6,604 crore (on a consolidated basis) in the third quarter of the current financial year, supported by growth across branded prescriptions, trade generics, and consumer health, the pharma major said in an exchange filing.
A CNBC-TV18 poll estimated Cipla's revenue at 6,473.4 crore. Cipla had posted a revenue of ₹5,811 crore in Q3FY23.
Cipla's net profit for the quarter under review jumped 31.8% to ₹1,056 crore, better than the CNBC-TV18 poll estimate of ₹1,020.4 crore. The pharma major had posted a net profit of ₹801 crore in the same period a year ago.
Cipla's EBITDA (earnings before interest, taxes, depreciation, and amortization) in the third quarter came in at ₹1,747.7 crore, rising 24% against ₹1,408.4 crore it had posted in the October-December quarter last year.
Cipla's margin jumped to its highest-ever 26.5% in the quarter under review. It had posted a margin of 24.2% in the same quarter a year ago.
In North America, Cipa posted its highest-ever quarter at $230 million at 18% YoY growth, backed by continuing momentum in key assets and robust demand in base business.
Another key market,
South Africa, also recorded a 15% YoY increase in revenue in local currency terms, supported by positive traction in prescription, OTC, and tender.
Cipla's research and development (R&D) investments stand at ₹400 crore, or 6.1% of sales, higher by 10% YoY, driven by product filings and developmental efforts.
On
Cipla's Q3 results, Umang Vohra, MD and Global CEO of the pharma major said, "I am happy to announce results for yet another quarter which further established our strengths of our core business in India, North America, and South Africa. Our topline growth for the quarter was at an impressive 14% YoY with strong EBITDA margins at 26.3%... Our focus continues on expansion in chronic therapies, growing big brands, global wellness, as well as developing our R&D pipeline in respiratory and peptides. We will continue to focus on driving profitable growth across businesses.”
